How to access Vumerity from Jordan, the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
A Jordanian patient with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary-progressive disease, may receive a prescription for Vumerity (diroximel fumarate) from their treating neurologist. Vumerity is FDA-approved for relapsing MS and developed by Biogen. It is not a controlled substance. In Jordan, Vumerity is not routinely registered for outpatient dispensing, and access is typically coordinated through the named-patient import pathway.
This guide explains the pathway, documentation your physician prepares, typical timing and how quotes work, and where Reserve Meds fits in.
Ask about Vumerity in Jordan
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
The clinical situation
Vumerity is an oral fumarate taken twice daily (titrated over one week from 231 mg to maintenance 462 mg twice daily). Diroximel fumarate is a prodrug of monomethyl fumarate, the same active metabolite as dimethyl fumarate (Tecfidera), with an improved GI tolerability profile in comparative studies. Eligibility anchors to confirmed relapsing MS diagnosis (McDonald criteria), baseline MRI, and monitoring plan for the class-level concerns, lymphopenia, liver enzymes, and PML risk stratification (JC virus antibody testing where indicated).
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Is Vumerity legally importable into Jordan?
Yes, through the Jordan Food and Drug Administration (JFDA) named-patient / special-access import framework. The mechanism permits a Jordanian-licensed physician to import a medicine not locally registered when (a) it is approved by a recognised reference authority such as the US FDA, (b) no clinically equivalent registered alternative is suitable (dimethyl fumarate may be considered; diroximel's GI-tolerability profile is distinct), (c) the physician accepts clinical responsibility, and (d) chain of custody is documented.
How the pathway works, step by step
- Consultation with your treating neurologist. MS diagnosis per McDonald criteria, MRI documentation, relapse history, and clinical rationale.
- Baseline assessment. Complete blood count with differential (lymphocyte monitoring), hepatic panel, JC virus antibody status, pregnancy planning discussion where applicable.
- JFDA named-patient application. The physician or hospital pharmacy files clinical rationale, patient reference, titration plan, and chain-of-custody commitment.
- US-side sourcing. Reserve Meds coordinates with our US-licensed pharmaceutical wholesale partner to secure Vumerity from authorised distribution under DSCSA.
- Ambient shipment. Vumerity ships under controlled ambient conditions with chain-of-custody documentation.
- Arrival and dispensing. The hospital pharmacy releases the bottles with titration instructions and monitoring schedule.
What documentation your physician needs
- Clinical rationale letter confirming relapsing MS and Vumerity as the indicated therapy
- Verification of Jordanian medical license
- MRI report and McDonald-criteria documentation
- Baseline CBC with differential, hepatic panel, JC virus antibody status
- Planned titration schedule and safety monitoring plan (lymphocytes, LFTs)
- Pregnancy planning discussion documentation where applicable
Reserve Meds provides a physician documentation kit bundling templates JFDA reviewers expect for MS disease-modifying therapy named-patient imports.
Costs and timing
Medicine price: quote on request. You get a written quote for your case before you commit. International logistics, JFDA documentation handling, and coordination add incremental cost. Reserve Meds issues a transparent quote at the start of intake.
We give you a written timeline estimate for your case before you commit.
If your clinical situation is time-sensitive, tell us at intake. We triage accordingly.
Reserve Meds's role
- Sourcing. Through our US-licensed pharmaceutical wholesale partner under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and JFDA review.
- Logistics. Ambient-controlled shipment to your prescribing hospital.
- Dedicated case lead. A named point of contact coordinating monthly refills and monitoring-cadence reminders.
What we do not do: We are not the prescriber, do not practise medicine, and are not the dispensing pharmacy. All clinical decisions remain with your treating neurologist.
Frequently asked
Is this legal in Jordan? Yes, when executed through the JFDA named-patient framework with appropriate documentation. See our trust and compliance page.
Is Vumerity a controlled substance? No. Diroximel fumarate is not a scheduled controlled substance.
How does Vumerity compare with Tecfidera? Both convert to monomethyl fumarate in vivo; Vumerity (diroximel fumarate) demonstrated a reduced incidence of GI adverse events in head-to-head studies, which can meaningfully affect adherence.
What monitoring is required? CBC with differential (lymphopenia can develop and warrants caution), hepatic enzymes, and JC virus antibody status per PML-risk monitoring, your neurologist sets the full cadence.
Will insurance cover this? Cash-pay is the default. Some Jordanian private insurers consider case by case; we supply documentation but do not process claims directly.
Next step
Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We are not a pharmacy, not the prescriber, and not the manufacturer. Cash-pay. Export-only (US → overseas). Composite case examples. Not medical advice.
Reviewed by the Reserve Meds clinical operations team. Last reviewed: 2026-04-23.
Frequently asked questions
How can I get Vumerity in Jordan if it is not approved or available there?
Reserve Meds coordinates US-sourced Vumerity for patients in Jordan through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for Jordan and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Vumerity in Jordan through a named-patient import?
Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Vumerity. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in Jordan, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Vumerity in Jordan through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Vumerity to a patient in Jordan?
Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Vumerity to your treating physician or hospital pharmacy in Jordan, with appropriate handling for the product.
How long does it take, and what does Vumerity in Jordan cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Vumerity in Jordan?
Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.